Research Article
ER81 Expression in Breast Cancers and Hyperplasia
Table 3
Comparison between ER81 expression and clinical data in breast cancers.
| | | ER81 negative (%) | ER81 positive (, %)* | P () |
| Age, years | | | | | āā¤50 | 48 | 22 (45.8) | 26 (54.2) | .814 | ā>50 | 33 | 16 (48.5) | 17 (51.5) | Menopause | | | | | āBefore | 46 | 22 (47.8) | 24 (52.2) | .483 | āAfter | 35 | 14 (40.0) | 21 (60.0) | Tumor size, cm | | | | | āā¤2 | 15 | 7 (46.7) | 8 (53.3) | .138 | ā2ā5 | 55 | 28 (50.9) | 27 (49.1) | ā>5 | 11 | 2 (18.2) | 9 (81.8) | Nodal status | | | | | āNegative | 43 | 18 (41.9) | 25 (58.1) | .463 | āPositive | 38 | 19 (50.0) | 19 (50.0) | Histological stage | | | | | āI | 10 | 6 (60.0) | 4 (40.0) | .246 | āII | 54 | 14 (25.9) | 30 (74.1) | āIII | 17 | 6 (35.3) | 11 (64.7) | ER | | | | | āNegative | 25 | 1 (4.0) | 24 (96.0) | .001 | āPositive | 56 | 22 (39.3) | 34 (60.7) | PR | | | | | āNegative | 28 | 3 (10.7) | 25 (89.3) | .010 | āPositive | 53 | 20 (37.7) | 33 (62.3) | HER2 amplification | | | | | āNegative | 53 | 19 (35.8) | 34 (64.2) | .041 | āPositive | 28 | 4 (14.3) | 24 (85.7) |
|
|
*Breast cancer tissues with were considered as ER81 positive expression.
|